Results 31 to 40 of about 111,913 (282)

A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation

open access: yesHepatology, EarlyView., 2022
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole   +12 more
wiley   +1 more source

Tacrolimus for the Treatment of Ulcerative Colitis [PDF]

open access: yesIntestinal Research, 2015
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients ...
Katsuyoshi Matsuoka   +7 more
doaj   +1 more source

Pregnancy after liver transplantation under tacrolimus [PDF]

open access: yes, 1997
Background. The maternal and fetal risk of pregnancy after organ transplantation under tacrolimus has not been reported. This was prospectively studied in 27 pregnancies by 21 female liver recipients who were treated with tacrolimus before and throughout
Armenti   +36 more
core   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

open access: yesHepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo   +19 more
wiley   +1 more source

Seasonal relapsing minimal change disease: a novel strategy for avoiding long-term immunosuppression. [PDF]

open access: yes, 2012
BACKGROUND: We describe the case of a young woman with seasonal allergic rhinitis who presented with signs of a lower respiratory tract infection, acute renal impairment and the nephrotic syndrome, demonstrated on biopsy to be due to minimal change ...
Cook, HT, Lawrence, C, Lightstone, L
core   +2 more sources

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle   +5 more
wiley   +1 more source

The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function

open access: yesTransplantation Direct, 2023
Background. Calcineurin inhibitors are inherent vasoconstrictors. Cerebral vasoconstriction can reduce cerebral blood flow (CBF), and negatively impact cerebrovascular response (CVR) to exercise, and cognitive function.
Irisa Mahaparn, MD   +6 more
doaj   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Hemoglobin and total bilirubin may affect tacrolimus clearance in liver transplant patient following the early postoperative period: a case report

open access: yesJournal of Medical Case Reports
Background Tacrolimus is a potent calcineurin inhibitor (CNI) that is principally used as a first-line immunosuppressant for the prophylaxis of allograft rejection in liver transplantation (LT) patients.
Vichapat Tharanon   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy